Ionis Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030
Updated on 03/29/2024
Ionis Pharmaceuticals Stock Forecast and Price Target
The average price target of $61.00 for Ionis Pharmaceuticals's stock set by three distinguished analysts in recent weeks would represent a potential upside of approximately 41.01% from the last closing price in March, 2024 if reached by the end of the year. This potential increase is based on a high estimate of $85.00 and a low estimate of $29.00. If you are interested in IONS stock, it is important to also consider its competitors.
41.01% Upside
Ionis Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Ionis Pharmaceuticals's Price has grown, moving from $0.00 to $0.00 – an increase of 100.00%. In the next year, analysts predict that Fair Value will jump to $46.93 – up 100.00% from the current level. Looking ahead to seven years, experts forecast that Fair Value will grow by 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
PFE Stock Forecast | Pfizer | Outperform |
2
|
$28.37 | Buy/Sell | $32.87 | 10.82% |
AMGN Stock Forecast | Amgen | Outperform |
4
|
$275.36 | Buy/Sell | $303.65 | 14.40% |
SAN Stock Forecast | Sanofi | Outperform |
16
|
88.32€ | Buy/Sell | 102.80€ | 21.15% |
REGN Stock Forecast | Regeneron Pharmaceuticals | Outperform |
2
|
$964.44 | Buy/Sell | $961.26 | 8.87% |
CSL Stock Forecast | CSL | Outperform |
12
|
$281.20 | Buy/Sell | $205.51 | -27.94% |
Ionis Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Ionis Pharmaceuticals's Revenue has grown, moving from $729.26M to $787.65M – an increase of 8.01%. In the following year, the 14 analysts surveyed believe that Ionis Pharmaceuticals's Revenue will decrease by 22.19%, reaching $612.87M. Looking ahead to seven years, experts forecast that Revenue will grow by 339.35%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
4568 Stock Forecast | Daiichi Sankyo Company | Buy |
4
|
¥4.83k | Buy/Sell | ¥5.24k | 18.04% |
4502 Stock Forecast | Takeda Pharmaceutical Company | Outperform |
5
|
¥4.31k | Buy/Sell | ¥4.74k | 6.63% |
MRNA Stock Forecast | Moderna | Outperform |
16
|
$111.98 | Buy/Sell | $135.42 | 11.09% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
BIIB Stock Forecast | Biogen | Outperform |
10
|
$230.07 | Buy/Sell | $299.62 | 29.09% |
ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$149.10 | Buy/Sell | $245.24 | 44.20% |
BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$86.00 | Buy/Sell | $111.56 | 26.40% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
INCY Stock Forecast | Incyte | Outperform |
9
|
$60.79 | Buy/Sell | $77.05 | 26.99% |
SRPT Stock Forecast | Sarepta Therapeutics | Outperform |
6
|
$121.58 | Buy/Sell | $158.66 | 35.71% |
JAZZ Stock Forecast | Jazz Pharmaceuticals | Outperform |
14
|
$116.63 | Buy/Sell | $188.32 | 59.52% |
Ionis Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, EBITDA for Ionis Pharmaceuticals has grown by 167.29%, going from $-126.91M to $-339.22M. For the next year, 3 analysts project Ionis Pharmaceuticals's EBITDA to drop by 16.25%, reaching $-284.11M. By 2030, professionals believe that Ionis Pharmaceuticals's EBITDA will decrease by 51.09%, reaching $-165.90M – a concerning trend for the company.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
EXEL Stock Forecast | Exelixis | Outperform |
16
|
$22.46 | Buy/Sell | $26.44 | 20.21% |
NTLA Stock Forecast | Intellia Therapeutics | Outperform |
8
|
$29.54 | Buy/Sell | $75.84 | 136.97% |
4516 Stock Forecast | Nippon Shinyaku | Outperform |
18
|
¥4.56k | Buy/Sell | ¥8.34k | 64.62% |
Ionis Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030
Ionis Pharmaceuticals's EBIT has grown in the last three years, jumping from $-142.33M to $-352.07M – an increase of 147.36%. In the next year, analysts predict that EBIT will reach $-453.93M – an increase of 28.93%. By 2030, professionals believe that Ionis Pharmaceuticals's EBIT will decrease by 564.73%, reaching $1.64B – a concerning trend for the company.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
DYN Stock Forecast | Dyne Therapeutics | Buy |
5
|
$25.55 | Buy/Sell | $28.13 | 40.90% |
DCPH Stock Forecast | Deciphera Pharmaceuticals | Outperform |
6
|
$16.54 | Buy/Sell | $23.40 | 39.06% |
BCRX Stock Forecast | BioCryst Pharmaceuticals | Outperform |
7
|
$5.32 | Buy/Sell | $14.09 | 97.37% |
Ionis Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Ionis Pharmaceuticals's EPS has grown, moving from $-0.35 to $0.00 – an increase of 100.00%. In the next year, analysts predict that EPS will jump to $-1.88 – up 100.00% from the current level. Looking ahead to seven years, experts forecast that EPS will grow by 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
WVE Stock Forecast | Wave Life Sciences | Outperform |
6
|
$6.80 | Buy/Sell | $9.21 | 61.76% |
PHARM Stock Forecast | Pharming Group N.V. | Buy |
16
|
1.07€ | Buy/Sell | 1.85€ | 66.36% |
FULC Stock Forecast | Fulcrum Therapeutics | Outperform |
9
|
$11.28 | Buy/Sell | $10.21 | 32.98% |